4D MOLECULAR THERAPEUTICS, INC.
Last · NASDAQ$12.20-0.16 (-1.29%)close · yahoo · 16h ago
Market cap$673.98M55.2M sh
P/E · TTM-4.6fwd -3.0 · eps -2.63 · loss
Beta2.74vs S&P 500
Div yield0.00%annual · TTM
52w range
$6.96$16.93
Volume633.0Ksession
| Revenue | $85.2M |
|---|---|
| Operating income | $-159.5M |
| Net income | $-140.1M |
| Free cash flow | $-109.6M |
| Operating margin | -187.2% |
| Net margin | -164.4% |
| Return on equity | -27.7% |
| Period | 2025 |
Loading chart…
OpenFilings analyst
Our analyst
From latest 10-K · 2026-03-18
- Sbc Revenue High
- Operating Cf Burn
- Net Margin Sharply Negative
- Cash Conversion Weak
- Cash Runway Low
- Accumulated Deficit High
Red flags
- Sbc Revenue High — SBC/Revenue 25.8%
- Operating Cf Burn — Negative operating cash flow
- Net Margin Sharply Negative — Net margin -164.4%
- Cash Conversion Weak — Cash conversion (CFO/Rev) -128.0%
- Cash Runway Low — Cash runway ~0.6 years
- Accumulated Deficit High — Accumulated deficit / equity 142%
Upcoming earnings
9:00 PM UTC+1
Period
Sep 2026
Est. EPS
−$1.05
Est. revenue
3.1M
Press & signals
- GlobeNewswire
4DMT Announces New Employment Inducement Grants
- GlobeNewswire
4DMT Announces New Employment Inducement Grants
- GlobeNewswire
4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
The rest of this company's wire — with summaries and source links — is part of Pro.
See plans